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Abstract
Background: Proteolytic degradation of extracellular matrix is a crucial step in the healing of incisional skin wounds. Thus,
healing of skin wounds is delayed by either plasminogen-deficiency or by treatment with the broad-spectrum
metalloproteinase (MP) inhibitor Galardin alone, while the two perturbations combined completely prevent wound
healing. Both urokinase-type plasminogen activator and several matrix metallo proteinases (MMPs), such as MMP-3, -9 and
-13, are expressed in the leading-edge keratinocytes of skin wounds, which may account for this phenotypic overlap
between these classes of proteases.
Methodology: To further test that hypothesis we generated Mmp13;Plau and Mmp13;Plg double-deficient mice in a cross
between Mmp13- and Plau-deficient mice as well as Mmp13- and Plg-deficient mice. These mice were examined for normal
physiology in a large cohort study and in a well-characterized skin wound healing model, in which we made incisional
20 mm-long full-thickness skin wounds.
Principal Findings: While mice that are deficient in Mmp13 have a mean healing time indistinguishable to wild-type mice,
wound healing in both Plau- and Plg-deficient mice is significantly delayed. Histological analysis of healed wounds revealed
a significant increase in keratin 10/14 immunoreactive layers of kerationcytes in the skin surface in Mmp13;Plau double-
deficient mice. Furthermore, we observe, by immunohistological analysis, an aberrant angiogenic pattern during wound
healing induced by Plau-deficiency, which has not previously been described.
Conclusions: We demonstrate a phenotypic overlap, defined as an additional delay in wound healing in the double-
deficient mice compared to the individual single-deficient mice, between MMP-13 and the plasminogen activation system
in the process of wound healing, but not during gestation and in postnatal development. Thus, a dual targeting of uPA and
MMP-13 might be a possible future strategy in designing therapies aimed at tissue repair or other pathological processes,
such as cancer invasion, where proteolytic degradation is a hallmark.
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Introduction
Proteolytic degradation and remodeling of the extracellular
matrix (ECM) is essential for several physiological and pathological
processes, such as embryonic development, mammary gland
morphogenesis, tissue remodeling and repair, cancer invasion
and metastasis [1–7]. Matrix metalloproteinases (MMPs) are a
family of 24 human extracellular zinc-dependent endopeptidases,
some of which are capable of degrading a variety of ECM
components. In addition, other substrates for MMPs include
growth factors and cytokines and other proteases [8] (for a detailed
review see [9]). MMP-13, or collagenase-3, is among the limited
numbers of MMPs that can cleave the fibrillar collagens (I, II and
III), being particularly potent against collagen II [10], the main
collagen constituent in cartilage. The expression of MMP-13 is
seen in numerous cancer types, particularly carcinomas [11], and
it has been suggested that MMP-13 could be an indicator for the
invasive capacity of squamous cell carcinomas (SCCs) [12,13].
The plasminogen activation (PA) system of serine proteases is an
additional extracellular proteolytic system involved in physiolog-
ical and pathological tissue remodeling [14]. Plasmin, the main
fibrinolytic enzyme in the body, is formed from plasminogen (Plg)
by proteolytic cleavage by one of three Plg activators, the
urokinase type (uPA), tissue type (tPA) [15] or plasma kallikrein
[16]. While uPA converts Plg to plasmin within tissues, tPA
generates plasmin for thrombolysis. Besides fibrin, other major
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pro-uPA and, at least in vitro, pro-MMPs including MMP-13 [17].
While Plg-deficiency has serious physiological consequences in
both mice and humans [18–20], the effects of Plau- (the gene
designation for uPA) deficiency are less pronounced [21]. How-
ever, numerous prognostic studies have correlated high uPA
protein levels in tumor tissue and blood samples with poor
prognosis in many types of cancers [14]. While uPA in some types
of cancers is expressed by stromal cells such as fibroblasts and
macrophages, uPA in SCCs is expressed by the cancer cells
themselves [22]. Several components of the MMP and PA families
have a very similar expression pattern in cancer invasion and
certain types of non-neoplastic tissue-remodeling, such as wound
healing. It has therefore been suggested that cancer invasion can
be viewed as tissue remodeling gone out of control [23–25]. In
both skin SCC and skin wound healing, epithelial cells (cancer cells
and keratinocytes) express MMP-13 and uPA [22,26–30] and in
mice MMP-13 appears to be the main collagenase involved in
epidermal keratinocyte migration across a collagen- and fibrin-rich
provisional matrix in vitro [31].
Wound healing in skin involves three partially overlapping
phases: inflammation, proliferation and tissue remodeling. During
proliferation, keratinocytes migrate and hyperproliferate at the
wound edge, leading to coverage of the wound with a new
epidermis, a process called re-epithelialization [25,32]. Different
proteases have been implicated in the various phases of wound
healing, with MMPs and serine proteases being the most
important [33]. Mice deficient in Plg show severely impaired
wound healing, due to a diminished ability of the migrating
keratinocytes to dissect the fibrin-rich matrix [19,34]. Time to
complete wound healing in Plau-deficient mice has been shown to
be only slightly delayed, although re-epithelialization at day 10
after wounding was 55% lower than in wild-type mice, whereas no
delay was observed in tpa-deficient mice [16]. In addition to
MMP-13, several MMPs including MMP-3 and -9, are expressed
in murine leading edge kerationocytes [27]. Treatment with the
broad-spectrum MP inhibitor Galardin, which is inhibiting a
number of MMPs, ADAMS and ADAMTSs although with
different IC50 values [35,36] causes a delay in wound healing
and effects on re-epithelialization very similar to those observed in
Plg-deficient mice [19]. However, when Plg-deficient mice are
treated with Galardin, healing is completely arrested, demonstrat-
ing a phenotypic overlap between the two families of matrix-
degrading proteases in wound healing [19,27]. The initial
characteriations of Mmp-deficient mice, except for Mmp14, have
only revealed subtle phenotypes during embryonic development
and skin wound healing [for reviews see [6,37]]. This could signify
a non-vital involvement during embryonic development. It is also
conceivable that the apparent dispensability of the MMPs can be
explained by enzymatic functional overlap, compensatory upre-
gulation or adaptive development, as has been exemplified by the
generation of three individual MMP double-deficient mice [38–
40] and Plau;Plat double-deficient mice [16,21]. Since some MMPs
have been shown to have overlapping substrates with the
plasminogen activation system [9,41] we have, by genetic means,
generated mice deficient in Mmp2 and Plg or Mmp9 and Plg by
intercrosses of double heterozygous Mmp2;Plg or Mmp9;Plg mice,
respectively. This resulted in a genotypic distribution in accor-
dance with the expected Mendelian distribution for Mmp2;Plg
offspring whereas a non-Mendelian distributuion was observed for
Mmp9;Plg offspring [42,43]. Furthermore, we were not able to
demonstrate any phenotypic overlap between MMP-2 and Plg or
MMP-9 and Plg during wound healing [42,43]. Thus, it still
remains to be clarified which MMP, or which combinations of
MMPs, are responsible for the phenotypic overlap with plasmin
during wound healing. To address this further, we have generated
mice that are double-deficient in Mmp13 and Plau, the plasmin-
ogen activator most important for Plg activation in tissues. In a
thoroughly characterized wound healing model [16,27], where a
20 mm full thickness incisional skin wound is inflicted along the
back midline of an anaesthetized mouse, we demonstrated a
phenotypic overlap between MMP-13 and uPA, defined as an
additional delay in wound healing in the double-deficient mice
compared to the single-deficient mice. This finding was substan-




The generation of the Mmp13-, Plg- and Plau-deficient mice was
previously described [18,21,39]. Both strains were backcrossed
more than 18 generations to FVB/n. Heterozygous Mmp13 and
Plau mice were crossed to obtain an F1 generation of double
heterozygous FVB-Mmp-13
+/2;Plau
+/2 siblings. These mice were
crossed to establish an F2 generation cohort from which four










2/2. Similarly, heterozygous Plg gene-deficient mice back-
crossed into an FVB/n background for 16 generations (Panum
Institue, Copenhagen, Denmark) were mated with heterozygous
Mmp13 gene-deficient mice that were backcrossed into an FVB/n
background for 9 generations to produce the F1 generation of
double heterozygous FVB-Mmp13
+/2;Plg
+/2 siblings. These F1
mice were crossed to produce an F2 generation from which four
groups of siblings were selected for expermiments: FVB-Mmp13
+/+;
Plg
+/+,F V B - Mmp13
2/2;Plg





2/2. Genotyping was performed on chromosomal
DNA purified from tail tips by multiplex PCRusingMmp13[21], Plau
[21] and Plg [18] primers. All animal experiments were conducted at
The Department of Experimental Medicine, University of Copenha-
gen and Rigshospitalet, Copenhagen, Denmark, in accordance with
institutional and national guidelines (permissions # 2007/561–1053).
The review board at the Faculty of Health Science, University of
Copenhagen (P06–114), approved this study. The mice were kept in
singleventilated cages with free accessto standard food and water.An
observer unaware of the genotype of the mice performed all
experimental evaluations.
Skin Wounding
Six- to eight-week-old mice were anesthetized by intraperitoneal
administration of a 1:1 mixture of Dormicum (Roche, Basel,
Switzerland) and Hypnorm (Janssen-Cilag Ltd, High Wycombe,
UK) and shaved on the back before an incisional 20 mm-long full-
thickness skin wound was made on the mice mid-dorsally with a
scalpel. After wounding the mice were caged individually until
termination of the experiment. The wounds were not dressed or
sutured and they were observed and measured every second day
until healing or isolation of tissue at the 14-day time point.
Complete healing of the wound was defined by loss of wound
crust. Previous studies revealed that this is an easy, robust, and
reproducible method for analysis of overall healing of large
incisional wound [16].
Tissue Preparation
Mice were anesthetized as above followed by intracardial
perfusion with 10 ml ice-cold phosphatebuffered saline (PBS) and
4% paraformaldehyde (PFA). The wound areas were removed
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and fixed in 4% PFA overnight at 4uC before they were em-
bedded in paraffin. The sections were cut perpendicular to the
longitudinal direction of the wounds. For histological analysis, a
total of 77 mice were wounded, from which tissue was isolated for
each of the four genotypes (wild-type, Mmp13-deficient, Plau-
deficient and Mmp13;Plau double-deficient).
Immunohistochemistry
Tissue sections were stained with the following antibodies:
rabbit anti-mouse keratin 10 (1:2000, BabCO, Richmond, CA,
USA), rabbit anti-mouse keratin 14 (1:2000, Covance, Berkeley,
CA, USA), rat anti-mouse CD34 (1:100, HyCult Biotechnology,
Uden, The Netherlands) and rat anti-mouse F4/80 (BM8) (1:200,
eBioscience, San Diego, CA, USA). Tissue sections were
deparaffinized in xylene and hydrated through graded ethanol/
water dilutions. For collagen staining, sections were stained in
Weigert’s haematoxylin for 5 min, washed for 10 min in running
tap water, stained for 10 min in 0.1% Picrosirius Red solution
(Amplicon, Skovlunde, Denmark) followed by washes in two
changes of acidified water (0.5% acetic acid) and rehydration in
ethanol. For antibody staining, antigen retrieval was carried out by
incubation in proteinase K for 15 min at 37uC (keratins 10/14,
F4/80) or in citrate buffer pH 6.0 for 10 min at 98uC (CD34).
After rinsing with water and TBS-T, endogenous peroxidase was
quenched with 1% H2O2 for 15 min. For CD34 staining,
endogenous biotin was blocked using a Biotin Blocking System
(Dako, Glostrup, Denmark), followed by incubation with primary
antibody over-night at 4uC, incubation with biotinconjugated
rabbit anti-rat (CD34) and 30 min incubation with StreptAB-
Copmplex/HRP (Dako). For F4/80 staining, sections were
incubated with primary antibody for two hours at room
temperature followed by secondary rabbit anti-rat IgG. For
keratin 10/14, and F4/80 staining, sections were incubated in
EnVision+ System Labelled Polymer-HRP Anti-rabbit (Dako) and
all antibodies were detected using VectorH NovaRED
TM substrate
kit (Vector Laboratories, Burlingame, CA, USA). Controls without
primary antibody were negative for unspecific staining.
Computer-assisted morphometry
Keratinocyte migration of 14 days old skin wounds was
measured by histological analysis of tissue sections immunohisto-
chemically stained for cytokeratins as described [16]. Image
analysis was performed using the Visiomorph software package
(Visiopharm, Hørsholm, Denmark).
Statistical Analysis
The GraphPad Prism software package (version 5.0) (GraphPad
Software Inc., San Diego, CA, USA) was used for statistical
analysis. Genotypic distribution was analyzed by X
2-test. Pre-
specified tests of hypothesis comparing experimental groups were
carried out using two-tailed t-tests. A p-value of 0.05 was set as the
level of significance.
Results
Gestation is unaffected by simultaneous lack of Mmp13
and either Plau or Plg
In order to examine and compare the effect of lack of either Plau
or Plg combined with Mmp13- deficiency during gestation, we set
out to generate Mmp13;Plau and Mmp13;Plg double-deficient mice.
Mice lacking one or more Mmp13 and Plau alleles were generated
by inter-crosses of doubleheterozygous F1 parents. Analysis of the
weaned F2 offspring revealed a Mendelian distribution (X
2-test,
p=0.656, Table 1). These results demonstrate that concomitant
ablation of Mmp13 and Plau did not affect the outcome of gestation
and post-natal survival as determined by genotyping of the weaned
offspring. In order to test whether complete ablation of Plg
together with simultaneous lack of Mmp13 is detrimental for
gestation, the genotypes of weaned F2 offspring were analyzed
revealing a Mendelian distribution (X
2-test, p=0.208, Table 1).
Taken together these results demonstrate that lack of Mmp13
combined with lack of either Plau or Plg is dispensable for
gestation.
Phenotypic characterization of unchallenged
Mmp13;Plau double-deficient mice
To characterize Mmp13;Plau double-deficient mice with respect
to development of spontaneous phenotypes during postnatal life,
we selected four groups of offspring; 16 wild-type (9 males and 7
females), 14 Mmp13-deficient (8 males and 6 females), 13 Plau-
deficient (7 males and 6 females) and 9 Mmp13;Plau double-
deficient mice (6 males and 3 females). These mice were weighed
and observed weekly until the age of six months for development
of overt spontaneous phenotypes. Of these mice, 1 wild-type
(female), no Mmp13-deficient, 4 Plau-deficient (1 male and 3
females) and 2 Mmp13;Plau double-deficient mice (2 females) died
for unknown reasons (non-significant by Logrank test) (Figure 1A).
The mice displayed no overt phenotypic differences and there was
no difference in weight at any time point (data not shown).
Additionally, like Mmp13- and Plau-deficient mice, both male and
female Mmp13;Plau double-deficient mice were fertile and the
Table 1. Genetic distribution of F2 offspring
Mmp13;Plau F2 Mmp13;Plg F2
Obs. (%) Exp. (%) Obs. (%) Exp. (%)
1. ++/++ 57 53 35 43
(6.75) (6.25) (5.15) (6.25)
2. +2/++ 109 106 87 85
(12.91) (12.50) (12.79) (12.50)
3. ++/2+ 93 106 105 85
(11.02) (12.50) (15.44) (12.50)
4. +2/+2 226 211 173 170
(26.78) (25.00) (25.44) (25.00)
5. 22/++ 55 53 29 43
(6.52) (6.25) (4.26) (6.25)
6. 22/2+ 112 106 80 85
(13.27) (12.50) (11.76) (12.50)
7. ++/22 48 53 43 43
(5.69) (6.25) (6.32) (6.25)
8. +2/22 101 106 83 85
(11.97) (12.50) (12.20) (12.50)
9. 22/22 43 53 45 43
(5.09) (6.25) (6.62) (6.25)
Total 844 844 680 680
X
2-test p=0.656 p=0.208
The F2 offspring from interbreeding of double-heterozygous F1 breeding pairs
(Mmp13;Plau and Mmp13;Plg) were genotyped at weaning. The numbers in
brackets indicate the calculated incidence percentage.
doi:10.1371/journal.pone.0016954.t001
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weaning (data not shown).
Mmp13 mRNA is expressed in hypertrophic chondrocytes and
in the primary ossification center and mice lacking MMP-13
display an altered endochondral bone development which is
resolved by 12 weeks of age [39]. Furthermore, Mmp13-deficient
mice have increased tibia trabecular bone, a phenotype that
progresses with age and is still apparent at 16 weeks of age, but
resolved by one year of age [39]. We measured the length of
femurs and tibiae at six months and found the femurs to be
significantly shorter in Mmp13-deficient and Mmp13;Plau double-
deficient mice compared to wild-type mice (p=0.019 and 0.045),
while there was no difference between wildtype and Plau-deficient
mice (Figure 1B). There was no difference in tibia length between
any of the four groups (data not shown). We also stained sections of
the same femurs and tibiae with PicroSirius Red to look at
trabecular bone, but found no differences between the four groups
of offspring (data not shown).
Fibrin and fibronectin are substrates of plasmin, which is
generated by uPA from the inactive precursor Plg [44], and mice
deficient in uPA are known to develop spontaneous hepatic fibrin
deposits [21]. Mmp13 has been shown to be expressed by
macrophages in murine livers where it is involved in mediating
the regression of hepatic fibrosis [45] and MMP-13 activity against
fibrinogen has been shown in vitro [46]. Thus, to examine a
possible molecular functional overlap between uPA and MMP-13
on fibrinolysis, we measured the degree of fibrin accumulation in
the mouse livers from all four groups of offspring. As expected we
found fibrin plaque deposition to be significantly increased in Plau-
deficient mice compared to wild-type mice (p=0.005), and also in
Mmp13;Plau double-deficient mice compared to wild-type mice
(p=0.014) (Figure 1, C–G). However, there was no difference
between wild-type and Mmp13-deficient mice or Plau-deficient and
Mmp13;Plau double-deficient mice, indicating that there is no
molecular functional overlap between uPA and MMP-13 during
postnatal fibrinolysis of the liver.
Figure 1. Survival, femur length and hepatic fibrin deposition in Mmp13;Plau double-deficient cohort mice. (A) Four genotype groups
of siblings were selected for a survival cohort. (B) Femurs were removed from wild-type, Mmp13-deficient, Plau-deficient and Mmp13;Plau double-
deficient mice at six months of age. Data are represented as scatter plots and mean values are depicted as horizontal lines. (C–G) Livers from mice
were removed when mice were six months old, processed for immunohistochemistry and stained for fibrin. (D–G) Scale bar =0.2 mm. (C) The total
area of liver cells positive for fibrin per mille of liver cells negative for fibrin was quantified. Bars represent the means 6 SEM of each group. *p#0.05;
**p#0.01.
doi:10.1371/journal.pone.0016954.g001
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plasminogen activation system in skin wound healing
Thus, observing no overt spontaneous phenotypes as a
consequence of combined deficiency of Mmp13 and Plau, we next
initiated a wound healing study in which we inflicted standardized
20 mm-long full-thickness incisional skin wounds on wild-type
(n=15), Mmp13-deficient (n=19), Plau-deficient (n=16) and
Mmp13;Plau double-deficient (n=15) mice. The wounds were
observed and lengths were measured every second day until
healing. Complete healing of the wound was defined by loss of
wound crust and closure of the incision interface with restoration
of the epidermal covering. We found mice that are deficient in
Mmp13 to have a mean healing time indistinguishable from wild-
type mice (16.3 versus 15.7 days), while Plau-deficient mice had a
mean healing time that was delayed to 20.1 days (wild-type versus
Plau
2/2; p=0.002) (Figure 2, A and B). The mean healing time
was increased to 25.2 days in mice that are deficient in both
Mmp13 and Plau, a significant delay compared to wildtype mice
(p,0.001) and also to the Mmp13( p ,0.001) and Plau (p=0.016)
single-deficient mice (Figure 2, A and B). The lack of an effect on
wound healing in Mmp13-deficient mice has been demonstrated
before and was expected [47]. We have previously examined the
effect of Plau-deficiency in wound healing in a C57Bl6J
background and found no effect on the mean healing time [16].
The phenotypic overlap between MMP-13 and the PA system
was additionally substantiated by an independent wound healing
study in wild-type (n=11), Mmp13-deficient (n=10), Plg-deficient
(n=17) and Mmp13;Plg double-deficient (n=13) mice. As above,
we found mice that are deficient in Mmp13 to have a mean healing
time indistinguishable from wild-type mice (17.0 versus 15.6 days),
while Plg-deficient mice had a mean healing time that was delayed
to 34.1 days (wild-type versus Plg2/2;p ,0.001) (Figure 2, C and
D). The mean healing time was increased to 41.2 days in mice
deficient in both Mmp13 and Plg, a significant delay compared to
wild-type mice (p,0.001) and also to the Mmp13 (p,0.001) and
Plg (p=0.001) single-deficient mice (Figure 2, C and D). Thus,
during wound healing there is a phenotypic overlap between
MMP-13 and uPA as well as MMP-13 and Plg.
Histological examination of keratinocyte migration
Coverage of the wound with a new epidermis, a process called
re-epithelialization, begins with keratinocyte hyperproliferation at
the wound edges [25]. This is followed by migration of the
keratinocytes, which is evident about 3–5 days after wounding
[19]. We next examined histological sections of keratin-stained
wounds removed 14 days after incision, when the wound healing
curves for Plau- and Mmp13;Plau-double-deficient mice begin to
separate, as well as two days after complete healing. After 14 days,
the keratinocytes covered the wounds in 100% of the wildtype
mice analyzed (Figure 3A), and only 12.5% of the wounds from
the Mmp13-deficient mice were not covered (Figure 3B). Contrary
to this, although the wound crust was clearly visible, 90% of the
wounds from Plau-deficient and 70% from the Mmp13;Plau-
double-deficient mice were not covered by keratinocytes at this
time-point, demonstrating that the re-epithelialization is severely
delayed (Figure 3, C and D). Apparently, this delay is not due to
the migrating tips being blunt-ended, as they have been shown to
be in wounds from mice deficient in Plg [19,27] or in mice treated
with the broad-spectrum MMP inhibitor Galardin [27]. The
migrating tips in wounds from Mmp13;Plau double-deficient mice
displayed both the phenotype characteristic of a wild-type wound
where the leading-edge keratinocytes form a wedge-like structure
(Figure 3E) as well as having blunt-ended tips (Figure 3F). This is
true also for the Plau-deficient mice (data not shown).
We next quantified the re-epithelialization by measuring the
relative migration of the keratinocytes, determined as the distance
from the wound edge to the front of the leading-edge
keratinocytes, divided by the distance between the two wound
edges. At 14 days after wounding, we found the relative migration
distances of the keratinocytes to be significantly lower in Plau- and
Mmp13;Plau double-deficient wounds compared to wild-type
wounds (p,0.001 and p=0.002) (Figure 3K). However, there is
no difference in relative migration between Plau- and Mmp13;Plau
double-deficient wounds at this time-point.
When examining the wounds microscopically we noticed that
in the Mmp13;Plau double-deficient wounds the epidermal layer
was often multilayered with notable accumulation of keratino-
cytes protruding into the dermis below (Figure 3, D and J).
Thus, we quantitated the keratin 10/14 immunoreactive area of
the multilayered epidermis from the wound edge to the leading
edge keratinocytes by computerassisted morphometry. We
found that in the 14 day wounds the keratinocyte area in the
Mmp13;Plau double-deficient wounds was significantly larger
than in wild-type wounds (p=0.010) (Figure 3L). Although
notable, at this time point the increase was not significantly
different from the areas measured in wounds single-deficient for
either Mmp13 or Plau. However, when measuring the keratino-
cyte area in healed wounds the difference between Mmp13;Plau
double-deficient wounds and the other three genotypes became
more evident. Healed wild-type, Mmp13-a n dPlau-deficient
wounds were at this stage indistinguishable from each other with
the epidermis forming a thin layer distinct from the underlying
dermis (Figure 3, G–I). In contrast, the keratin 10/14
immunoreactive epidermal layers seen in the healed Mmp13;Plau
double-deficient wounds were significantly larger and with
notable protusion into the dermis compared to both wild-type
(p=0.037), Mmp13- (p=0.043) and Plau-deficient wounds
(p=0.034) (Figure 3M). This finding demonstrates that the
turnover of the multilayered epidermis, consisting of both basal
and superbasel kerationcytes, is significantly delayed in
Mmp13;Plau double-deficient healed wounds. This indicates that
the phenotypic overlap between MMP-13 and uPA causing a
delay in wound healing also causes a delayed turnover of the
epidermis posthealing.
Altered wound angiogenesis in Mmp13;Plau mice
During the phase of granulation tissue formation in wound
healing, angiogenesis is stimulated by various growth factors,
such as vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), basic fibroblast growth factor (bFGF) and
transforming growth factor b (TGF-b), derived from wound
macrophages, keratinocytes and damaged endothelial cells
[48,49]. In addition, angiogenesis is dependent also on the
proteolytic activity of plasmin and MMPs [7]. We therefore
examined the effect of MMP-13 and uPA on angiogenesis in
day 14 wounds by CD34 immunostaining. We found no
apparent difference in the size or density of vessels when
comparing wounds from wild-type, Mmp13-, Plau-o r
Mmp13;Plau double-deficient mice (Figure 4, A–H). The lack
of effect on vessel size and density in Mmp13-deficient wounds is
consistent with findings in another study on MMP-13 in wound
healing [47], but in contrast to findings in a study where vessel
density was found to be decreased [50]. Despite the lack of
effect on vessel size and density in our study, we observed an
altered CD34 expression pattern in wounds single-deficient for
Plau or Mmp13;Plau double-deficient. Whereas the vessels in
wild-type and Mmp13-deficient wounds were found exclusively
in the dermis, concentrated at the interface between epidermis
Phenotypic Overlap between MMP13 and Plasmin
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epidermal layer in the Plau-a n dMmp13;Plau double-deficient
wounds (Figure 4, E–H). Since this aberrant pattern was the
same in Plau-c o m p a r e dt oMmp13;Plau double-deficient
wounds, it suggests that the effect is due to the lack of uPA
alone and does not explain the keratinocyte build-up and
delayed wound healing observed in Mmp13;Plau double-
deficient mice.
To determine the inflammatory response, wound tissue sections
were also analyzed for infiltration of macrophages by F4/80
staining, but no difference between the four genotype groups was
observed (data not shown). Additionally, immunohistochemical
staining for laminin-5, which is expressed by leading edge
keratinocytes and is a common substrate for both plasmin [51]
and MMP-13 [52], revealed no aberrant pattern between any of
the four genotype groups.
Discussion
In this study we show that there is a phenotypic overlap between
MMP-13 and the PA system in skin wound healing. We have
previously reported that Plg-deficiency in mice results in a delayed
wound healing. The primary reason for this delay is most likely a
decreased ability of the keratinocytes to dissect their way
proteolytically through the fibrin-rich extracellular matrix, which
is substantiated by the fibrillar deposits seen in front of and below
the epidermal outgrowth in Plg-deficient mice [27]. Nevertheless,
the additional lack of fibrinogen does not completely rescue the
impaired wound healing in Plg-deficient mice, indicating that
plasmin has other substrates than fibrinogen during skin wound
healing [19]. Moreover, mice treated with the broad-spectrum MP
inhibitor Galardin have a delay in wound healing [19,27].
Although excessive amounts of fibrin below and in front of the
Figure 2. Time course of skin wound healing in Mmp13;Plau and Mmp13;Plg double-deficient mice. (A+C) The percentage fraction of mice
with complete re-epithelialization is plotted vs. time after incision of 20 mm long wounds. (B+D) The average wound length is plotted vs. time after
incision. Wound healing in Mmp13-deficient mice is indistinguishable from that in wild-type mice, while wound healing in both Plau- and Plg-
deficient mice is significantly delayed compared to wildtype wound healing (p=0.002 and p,0.001 in a two-tailed t-test). However, Mmp13;Plau and
Mmp13;Plg double-deficient mice have an additional significant delay in wound healing compared to either Plau-o rPlg-deficient mice (p=0.016 and
p,0.001 in a two-tailed t-test), indicating a phenotypic overlap between MMP-13 and the PA system.
doi:10.1371/journal.pone.0016954.g002
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significant difference in healing times between Galardin-treated
wild-type mice and Galardin-treated fibrinogen deficient mice
[19]. This indicates that reduced fibrinolysis is not the major cause
of the delay in wound healing induced by Galardin.
Although wound healing is delayed in both Plg-deficient and
Galardin-treated wild-type mice, wound healing is eventually
achieved. However, when Plg-deficient mice are treated with
Galardin healing is completely arrested, demonstrating that
protease activity is essential for wound healing and that there is
a phenotypic overlap between the PA- and the metalloprotease
system, including MMPs, ADAM and ADAMTS in this process
[27]. Both uPA and MMPs -3, -9 and –13, are expressed in the
leading-edge keratinocytes of skin wounds, which may account for
this very clear phenotypic overlap [27,29]. Wound healing studies
in mice deficient for MMPs -3, -9 and -13 have previously been
performed. Just as incisional wound healing in Mmp3-deficient
mice is not delayed compared to wild-type mice [53], there is
either no or marginal (depending on the wound healing model
used [50,54]) delay in wound healing in Mmp9-deficient mice [43].
Regarding wound healing in Mmp13-deficient mice, two contrast-
ing studies have been performed. In one study no differences in the
Figure 3. Kinetics of re-epithelialization in skin wounds in Mmp13;Plau double-deficient mice. Re-epithelialization of wounds is visualized
by immunostaining of keratinocytes with anti-mouse keratins 10 and 14 in wild-type (A+G), Mmp13-deficient (B+H), Plau-deficient (C+I) and
Mmp13;Plau double-deficient (D+J) mice. (C) black arrows mark the wound edge and red arrows point to the tip of the leading edge
keratinocytes. Scale bar =0.5 mm, except for (E+F) (insets of D showing the leading edge keratinocytes) where scale bare =0.2 mm. (K) Quantitative
evaluation of the relative migration distance of keratinocytes measured at day 14 after incision. With this method, complete re-epithelialization is
scored as 1.0 and each data point refers to an individual wound. The mean values are depicted as horizontal lines. (L+M) Quantitative evaluation of
the area of the multilayered epidermal layer measured from the wound edge to the leading edge kerationocytes by computerassisted morphometry.
Differences in experimental groups are measured by a two-tailed unpaired t-test. *p#0.05; **p#0.01; ***p#0.001).
doi:10.1371/journal.pone.0016954.g003
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formation or angiogenesis is seen when comparing wild-type and
Mmp13-deficient mice [47], while in the other study a delayed
wound closure and a decreased vascular density is observed in
Mmp13-deficient mice [50]. These discrepancies could be
explained by the different genetic background of mouse strains
used, or more likely by the differences in excisional wound sizes
(4 mm versus 8 mm). To investigate a possible phenotypic overlap
between MMP-13 and the PA system during normal physiology
and wound healing, we have generated mice double-deficient for
Mmp13 and Plau as well as double-deficient for Mmp13- and Plg.
The genotypic distribution of offspring from Mmp13;Plau and
Mmp13;Plg heterozygous parents follows Mendelian distributions,
suggesting that any possible molecular or phenotypic overlap
between MMP-13 and uPA/Plg does not influence embryonic
development and early post natal life. Additionally, the mice
displayed no overt phenotypic differences.
To reveal a possible phenotypic overlap between MMP-13 and
the PA system, we took advantage of a well-characterized skin
wound healing model in which we made incisional 20 mm-long
full-thickness skin wounds. We found that the combined deficiency
in Mmp13 and Plau/Plg results in a significant delay in wound
healing compared to Mmp13, Plau or Plg single-deficiencies,
demonstrating a phenotypic overlap between MMP-13 and
uPA/Plg. We have previously provided evidence that plasmin
cleavage of substrates other than fibrin(ogen) is rate-limiting for
incisional skin wound healing [19]. Furthermore, the accumula-
tion of fibrin(ogen) observed in front of keratinocytes in Plg-
deficient mice is not observed in Plau-deficient wounds [16]. Thus,
since we observe a phenotypic overlap, not only between MMP-13
and Plg but also between MMP-13 and uPA, we conclude that this
is not exclusively due to impaired fibrin dissolution.
We observe no phenotypic difference between Mmp13-deficient
and wild-type wounds suggesting that in the presence of uPA
activity the lack of MMP-13 is compensated for. However, as
detected by gelatin substrate zymography and fibrin overlay
zymography no detectable compensatory upregulation of gelati-
nase activity or plasminogen activator activities was observed in
the protease-deficient mice (data not shown).
One possible explanation for the additional delay in wound
healing observed in Mmp13;Plau double-deficient mice is that the
cleavage of one or more extracellular matrix components, which is
critical for keratinocyte migration, can be achieved by either
MMP-13 or uPA. We examined one such possible candidate,
laminin-5, which is expressed by leading edge keratinocytes and is
a common substrate for both plasmin [51] and MMP-13 [52].
However, we found no abberant expression pattern between the
four groups of genotypes when performing immunohistochemical
staining for laminin-5 in wounds. Thus, the existence, if any, of a
mutual target for MMP-13 and uPA, which is functionally
involved in keratinocyte migration still remains to be determined.
It would seem from our immunohistological examinations that
the additional delay in wound healing observed in the Mmp13;Plau
double-deficient mice is a result of hyperkeratosis, leading to a
compressed build-up of keratinocytes under the skin surface. We
examined the possible involvement of angiogenesis in this
phenotype and found that in the Plau- and Mmp13;Plau double-
deficient wounds the vessels protrude into the epidermal layer.
Interestingly, this is never observed in wild-type and Mmp13-
deficient wounds. It is well established that uPA is involved in the
regulation of vascular remodeling and angiogenesis, not only in
wound healing but also in tumors [55,56]. The aberrant pattern of
endothelial cells that we observe in the epidermis during wound
healing suggests that the resulting effect of Plau-deficiency is not as
simple as reduced vascular growth, since we observe no apparent
difference in the size or density of vessels. It would seem that Plau-
deficiency induces an imbalance between the various factors
regulating angiogenesis, disrupting this normally very well
Figure 4. Angiogenesis in skin wounds in Mmp13;Plau double-deficient mice. Angiogenesis in wounds removed 14 days after incision is
visualized by immunostaining of endothelial cells with antimouse CD34 in wild-type (A+B), Mmp13-deficient (C+D), Plau-deficient (E+F) and
Mmp13;Plau double-deficient (G+H) mice. The box insets in (A, C, E+G) indicate the magnified views shown in (B, D, F+H). In (F+H) the arrows mark
where the vessels protrude into the epidermal layer of the wounds. The scale bar in (A)=0.2 mm and is representative also for (C, E+G). The scale bar
in (B)=0.1 mm and is representative also for (D, F+H).
doi:10.1371/journal.pone.0016954.g004
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in Mmp13;Plau double-deficient wounds compared to Plau-
deficient wounds, and thus seems to be an effect related to Plau-
deficiency alone. However, it is conceivable that the induction of
angiogenesis in the epidermal layer induced by the lack of uPA, in
combination with a separate proteolytic effect of MMP-13 causes
the observed wound phenotype in the Mmp13;Plau double-
deficient mice. According to such a scenario the observed
phenotypic overlap between MMP-13 and the PA system during
wound healing is not due to the existence of a mutual proteolytic
substrate but rather two (or more) separate substrates with a
cummulative effect. Thus, the function of MMP-13 alone is
unmasked only when the PA system is simultaneously targeted.
It is very plausible that the phenotypic overlap between MMP-
13 and uPA observed in the process of wound healing applies
equally well to other normal or pathological tissue remodeling
processes. In particular, there are many parallels between wound
healing and cancer invasion [24,25]. Epithelial cells in different
types of human SCCs express both MMP-13 and uPA
[12,13,22,26,30], and it would be interesting to examine this
cancer type for a molecular and phenotypic overlap between the
two proteases MMP-13 and uPA. Also interesting is the parallel to
studies on MMP-13 and uPA in the murine MMTV-PyMT breast
cancer model. Although MMP-13 and uPA are both highly
expressed at the tumor-stroma border [57,58], only deficiency in
Plau causes a decreased lung metastasis volume [57], while
Mmp13-deficiency has no effect [58]. In light of our results, it
would be interesting to identify the effect of combined Mmp13- and
Plau-deficiency in the MMTV-PyMT model. In conclusion, we
have demonstrated a phenotypic overlap between MMP-13 and
the PA system during remodeling of the skin, but not during
gestation and postnatal development. It remains to be elucidated if
this phenotypic overlap is also present in other tissue repair and
remodeling events.
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